[go: up one dir, main page]

AR131001A1 - Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso - Google Patents

Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso

Info

Publication number
AR131001A1
AR131001A1 ARP230102999A ARP230102999A AR131001A1 AR 131001 A1 AR131001 A1 AR 131001A1 AR P230102999 A ARP230102999 A AR P230102999A AR P230102999 A ARP230102999 A AR P230102999A AR 131001 A1 AR131001 A1 AR 131001A1
Authority
AR
Argentina
Prior art keywords
methods
protein tyrosine
tyrosine phosphatase
compositions
phosphatase inhibitors
Prior art date
Application number
ARP230102999A
Other languages
English (en)
Inventor
Annapurna Pendri
Haibo Liu
Shoshana L Posy
Yucheng Mu
Joanne Jewett Bronson
Laura Akullian Dagostino
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR131001A1 publication Critical patent/AR131001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se divulgan compuestos de la fórmula (1) y se definen sales farmacéuticamente aceptables de los mismos, y composiciones farmacéuticas y combinaciones de los mismos, y métodos para utilizarlos como inhibidores de la proteína tirosina fosfatasa (PTPN2). Estos compuestos son útiles en el tratamiento del cáncer y enfermedades susceptibles a la inhibición de PTPN2.
ARP230102999A 2022-11-09 2023-11-08 Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso AR131001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263383021P 2022-11-09 2022-11-09

Publications (1)

Publication Number Publication Date
AR131001A1 true AR131001A1 (es) 2025-02-05

Family

ID=89164625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102999A AR131001A1 (es) 2022-11-09 2023-11-08 Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso

Country Status (8)

Country Link
US (1) US20240207238A1 (es)
EP (1) EP4615840A1 (es)
JP (1) JP2025538169A (es)
KR (1) KR20250090365A (es)
CN (1) CN120225517A (es)
AR (1) AR131001A1 (es)
TW (1) TW202434580A (es)
WO (1) WO2024102791A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7217762B2 (ja) * 2018-06-21 2023-02-03 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
CN116829555A (zh) * 2020-09-11 2023-09-29 卡里科生命科学有限责任公司 蛋白酪氨酸磷酸酶抑制剂及其使用方法
JP2024509962A (ja) * 2021-03-11 2024-03-05 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環及びその使用
EP4472957A1 (en) * 2022-02-02 2024-12-11 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2025538169A (ja) 2025-11-26
KR20250090365A (ko) 2025-06-19
EP4615840A1 (en) 2025-09-17
WO2024102791A1 (en) 2024-05-16
CN120225517A (zh) 2025-06-27
TW202434580A (zh) 2024-09-01
US20240207238A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
CL2023001738A1 (es) Inhibidores de prmt5
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
DOP2022000117A (es) Inhibidores de kras g12c
MX2023006145A (es) Inhibidores de prmt5 novedosos.
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CL2020002562A1 (es) (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
UY40587A (es) Inhibidores del inflamasoma nlrp3
ECSP22083772A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
AR131001A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
AR131413A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
AR131414A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
CL2025000087A1 (es) Compuestos inhibidores de tirosina quinasa 2 y uso.
CL2024001524A1 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.